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Background: In recent years, patients with cystic fibrosis (CF) have tended to experience a longer life expectancy
and higher quality of life. In this context, the aim of the present study was to evaluate and compare the demographic,
clinical, and laboratory markers of patients with CF during the last two decades at a CF referral center.
Methods: A retrospective study of the demographic, clinical, and laboratory markers for CF treatment at a CF referral
center was performed during two decades: 2000 (DI, 1990–2000, n = 104 patients) and 2010 (DII, 2000–2010, n = 181
patients).
Results: The following variables were less common in DI than in DII: (i) pancreatic insufficiency, (ii) meconium
ileus, (iii) diabetes mellitus, (iv) Burkholderia cepacia colonization, (v) moderate and severe Shwachman-Kulczycki
score (SKS), (vi) F508del mutation screening, (vii) patients without an identified CFTR mutation (class IV, V, or VI
mutation), (viii) patients above the 10th percentile for weight and height, (ix) restrictive lung disease, and (x) older
patients (p < 0.01). The following variables were more common in DI than in DII: (i) excellent and good SKS, (ii) F508del
heterozygous status, (iii) colonization by mucoid and nonmucoid Pseudomonas aeruginosa, (iv) obstructive lung disease,
and (v) minimal time for CF diagnosis (p < 0.01).
Conclusion: Clinical outcomes differed between the two decades. Demographic, clinical, and laboratory markers in
patients with CF are useful tools and should be encouraged in CF referral centers to determine the results of CF
management and treatment, enabling a better understanding of this disease and its clinical evolution. Early diagnosis
and management of CF will improve patients’ quality of life and life expectancy until personalized drug therapy is
possible for all patients with CF.
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The advances in knowledge of cystic fibrosis (CF:
#219700) have been striking in recent decades. Identifica-
tion of the cystic fibrosis transmembrane regulator gene
(CFTR) (region 7q3.11) [1-3], with nearly 2,000 mutations
identified in 2014 [4-6], has provided the knowledge base
for the genotypic and phenotypic characteristics of CF.
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unless otherwise stated.(quantitative and/or qualitative) of the CFTR protein, al-
tering chloride transport at the cell surface. This causes a
compensatory influx of sodium to maintain electroneu-
trality and a consequent influx of water, extracellular de-
hydration, and formation of thick mucus in the airways
[7]. Classic CF is characterized by pulmonary and gastro-
intestinal symptoms in the first few months of life [8].
The clinical manifestations of CF are variable, even
among patients with the same CFTR mutation [9,10]. Ad-
vances in CF treatment in the last several years are related
to therapies aimed at improving the quality of life and
management of the disease. These therapies include in-
haled drugs, respiratory therapy, individualized outpatient. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.biomedcentral.com/1471-2466/15/3care, treatment of comorbidities, genetic counseling, diet-
ary adaptation of pancreatic enzymes, nutritional supple-
ments, neonatal screening by immunoreactive trypsinogen
(IRT), antibiotic therapy, lung transplantation, and, more
recently, personalized drug therapy [i.e., ivacaftor for
G551D (rs75527207, c.1652G >A) mutation and eight
other mutations approved by the US Food and Drug
Administration] [11,12].
In developing countries, recent studies on CF are
scarce and a poor understanding of patient management
and CF progression during follow-up care exists in refer-
ral centers. In this context, the aim of the present study
was to evaluate and compare the demographic, clinical,
and laboratory markers in patients with CF treated at a
referral center in the last decade of the 20th century
(DI) and the first decade of the 21st century (DII).
Methods
A retrospective study in a CF referral center was per-
formed. Demographic, clinical, and laboratory data were
obtained from 104 patients with CF seen in the last dec-
ade of the 20th century, from 1990 (time zero) to 2000
(DI); all data were collected from the patients’ medical
records in the year 2000 [13]. The same data were ob-
tained from 181 patients with CF treated in the first dec-
ade of the present century, from 2001 (time zero) to
2010 (DII); all data were collected from the patients’
medical records in the year 2011. The number of pa-
tients with CF enrolled in both decades equaled the total
number of patients with CF followed at the referral cen-
ter in the stipulated timeframe. The diagnosis of CF was
confirmed by two sweat tests with chloride concentra-
tions of >60 mEq/L (gold standard diagnostic tool) and/
or identification of two CFTR mutations. Patients with
CF who had undergone lung transplantation were not
enrolled.
Demographic, clinical, and laboratory markers
The demographic, clinical, and laboratory variables ana-
lyzed in this study were sex (male/female), ethnicity
(Caucasian or non-Caucasian), age, age range, number
of deaths, clinical manifestations (respiratory and di-
gestive), age at diagnosis, comorbidities [pancreatic in-
sufficiency (PI), meconium ileus (MI), and diabetes
mellitus (DM)], nutritional status as determined by
weight and height on a growth curve (weight and
height below the 10th percentile), oxygen saturation
(SpO2) (>95%, 91%–95%, or <91%), sweat chloride level,
microorganisms in the sputum (Staphylococcus aureus,
mucoid and nonmucoid Pseudomonas aeruginosa, and
Burkholderia cepacia), spirometry findings (normal,
restrictive lung disease, obstructive lung disease, or
mixed respiratory disorder) [14], genetic screening for
the CFTR mutations [F508del (rs113993960, c.1521_1523delCTT), G542X (rs113993959, c.1624G >T), N1303K
(rs80034486, c.3909C >G), G551D, R553X (rs74597325,
c.1657C >T), and W1282X (rs77010898, c.3846G >A)],
Shwachman-Kulczycki score (SKS) (excellent or good,
mild, or moderate or severe) [15], and fecal fat.
Spirometry
Spirometric testing was performed according to the fol-
lowing American Thoracic Society standards [14]:
(i). Obstructive lung disease: less than the 5th
percentile of the ratio of the predicted forced
expiratory volume in the first second to the forced
vital capacity (FEV1/FVC). Reduction of flow in a
patient with low lung volume is not specific to small
airway disease. Concomitant decreases in FEV1 and
FVC are commonly caused by poor effort, but can
rarely reflect airflow obstruction. Confirmation of
airway obstruction requires lung volume
measurement.
(ii). Restrictive ventilatory disturbance: total lung
capacity below the 5th percentile of the predicted
value. Reduced FVC does not prove the presence of a
restrictive lung defect, but is suggestive of pulmonary
restriction when the FEV1/FVC is normal or
increased.
(iii). Mixed respiratory disorder: FEV1/FVC and lung
capacity below the 5th percentile of the predicted
value.
Spirometric testing was performed in patients >7 years
of age using a CPFS/D spirometer (Medical Graphics
Co., Saint Paul, MN, USA). The data were recorded by
PF BREEZE software vs 3.8B for Windows 95/98/NT
(Medical Graphics Co.) [14].
SKS analysis
The SKS was determined by two previously trained pro-
fessionals, and in case of disagreement, a third evaluator
was considered [15].
Sputum collection
The patients’ sputum was collected by spontaneous spu-
tum sampling, induction by physiotherapy maneuvers,
or collection of oropharyngeal swabs for analysis of the
microorganism colonizing or infecting the airways. Ex-
aminations were performed in the Pathology Labora-
tory at the Clinical Hospital of the State University of
Campinas.
IRT was implemented in our center in 2010. There-
fore, the comparative analysis of the two decades did not
include patients with CF who underwent neonatal
screening.
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The Statistical Package for the Social Sciences v.21.0
(SPSS, Inc., Chicago, IL, USA) was used for statistical
analysis [16]. For descriptive analysis, we used mean,
median, and standard deviation for continuous variables
and absolute frequency (percentage) for categorical vari-
ables. Fisher’s exact test and the χ2 test were performed
to compare the groups using categorical variables. In
cases of differences in the data between the periods ana-
lyzed, the odds ratio (OR) and 95% confidence interval
(95% CI) were calculated. The alpha value was 0.05. The
Ethics Committee in Research of the State University of
Campinas (#508/2008) approved this study.
Results
Table 1 compares the demographic, clinical, and labora-
tory variables of the patients with CF enrolled in this
study in the two above-described decades.
The following markers showed an association between
the two decades: digestive symptoms, comorbidities,
height and weight, microorganisms, spirometry, SKS,
F508del screening, and age range (Tables 2, 3, 4 and 5).
An overview of all data analyzed is shown in Figure 1.
Comparison of DI with DII revealed the following
in DI:
(i). fewer patients with digestive disease (OR = 0.295,
95% CI = 0.17–0.51);
(ii). fewer patients with MI (OR = 0.35, 95% CI = 0.11–
0.91) and DM (OR = 0.228, 95% CI = 0.07–0.61);
(iii). fewer patients with an altered fat balance
(OR = 0.534, 95% CI = 0.31–0.93);
(iv). more patients below the 10th percentile for weight
(OR = 4.21, 95% CI = 2.34–7.67) and height
(OR = 1.895, 95% CI = 1.08–3.34);
(v). a higher frequency of P. aeruginosa (OR = 2.495,
95% CI = 1.42–4.48) and concurrent mucoid and
nonmucoid P. aeruginosa (OR =3.65, 95%
CI = 2.11–6.38);
(vi). a lower frequency of B. cepacia (OR = 0.302, 95%
CI = 0.09–0.84);
(vii). a higher frequency of mixed respiratory disorders
(OR = 17.58, 95% CI = 4.70–98.87) and a lower
frequency of restrictive respiratory disorders
(OR = 0.231, 95% CI = 0.09–0.51);
(viii). a lower frequency of moderate and severe SKS
(OR = 0.491, 95% CI = 0.24–0.96) and a higher
frequency of excellent and good SKS (OR = 2.403;
95% CI = 1.40–4.16);
(ix). for F508del a heterozygosity mutation was more
frequent (OR = 5.445, 95% CI = 3.09–9.74) in CF
patients with two CFTR mutations screened and less
frequent for patients without an identified CFTR
mutation (OR = 0.235, 95% CI = 0.13–0.42); and(x). a higher frequency of patients in preschool
(OR = 2.602, 95% CI = 1.38–4.94) and fewer adult
patients (OR = 0.293, 95% CI = 0.13–0.60).
Figure 2 shows the age at onset of clinical symptoms
(Figure 2A) and at diagnosis (Figure 2B).
Discussion
Evolutionary studies of the clinical and laboratory char-
acteristics of patients with CF have been performed by
many organizations worldwide. The Cystic Fibrosis
Foundation [17] and the Cystic Fibrosis Trust [18] show
the annual records of patients and compare the clinical
outcomes in sequential decades. These data allow for ap-
propriate actions by healthcare institutions and govern-
ment and generate prospects for laboratory and clinical
research on CF. However; few studies in Brazil have re-
ported the characteristics of CF annually or in recent
decades.
Sex, ethnicity, and consanguinity
The sex prevalence was equal between the two decades.
The disease severity and energy demand are greater both
in patients with CF and during puberty, which may re-
sult in an increase in the long-term incidence of men
with CF [19]. However, this finding was not observed in
either DI or DII.
Another finding in this study relates to the prevalence
of Caucasian patients with CF. The CF referral center
considered is the same in two decades, and the enrolled
population comprised patients from the same region; the
patients were predominantly Caucasian. In this context,
summing the Caucasian prevalence and CF etiology,
which is intrinsically of Caucasian patients, values
of >90% for the Caucasian patients in the two decades
was expected.
The prevalence of consanguineous marriage was low
at nearly 5%. As a monogenic recessive disease, children
of consanguineous parents have a higher risk of develop-
ing CF. The public health policy in Brazil helps to lower
the risks associated with consanguineous marriages by
educating the population about these risks. This policy
resulted in a lower number of patients with CF with
consanguineous parents in DII than in DI.
Patient age
Patients in DII were older than those in DI. Age is a fac-
tor associated with SKS variability [20] because CF lung
disease is associated with a decline in lung function sec-
ondary to architectural deterioration of the airways
caused by the cycle of inflammation/infection with
chronic exacerbations due to bacterial infections [21].
Older patients constitute a major proportion of the
Table 1 Comparison of data (demographic, clinical, and laboratory markers) of patients with cystic fibrosis from a
Brazilian referral center during the decades of 1990 to 2000 and 2000 to 2010
Demographic and clinical
markers
Category DI (1990–2000) DII (2000–2010) p
Number of patients 104 181
Age Mean: 10 years
9 months ± 6.33 months
Mean :16 years
7 months ± 13.16 months
<0.001
Median: 9 years Median: 12 years 10 months
Range: 11 months
to 31 years 2 months
Range: 6 months
to 73 years 10 months
Sex Male 53.8% 49.7% 0.539
Female 46.2% 50.3%
Ethnicity Caucasian 93.3% 92.0% 0.818
NonCaucasian 6.7% 8.0%
Consanguineous parents 6.2% 1.1% 0.054
Manifestation Respiratory 89.4% 91.7% 0.528
Digestive 59.6% 83.3% <0.001
Onset of symptoms Mean: 16 months Mean: 91.75 months <0.001
Median: 3 months Median: 3 months
Range: 0–20 years Range: 0–60 years
Age at diagnosis Mean: 4 years 2 months Mean: 2 years 10 months <0.001
Median: 2 years 4 months Median: 2 years
Range: 0 to 29 years
11 months
Range: 0–60 years
Meconium ileus 5.8% 15.0% 0.021
Diabetes mellitus 4.8% 18.5% 0.001
Nutritional status Weight below 10th percentile 69.9% 35.71% <0.001
Height below 10th percentile 56.6% 40.82% 0.025
SpO2 >95% 59.5% 55.5% 0.713
91%–95% 32.9% 34.7%
<91% 7.6% 9.8%
Sweat test <60 mEq/L* 10.6% –
60–100 mEq/L 28.8% 40.51%
>100 mEq/L 60.6% 59.49%
Bacteria Staphylococcus aureus 80.2% 78.5% 0.880
Pseudomonas aeruginosa 76.0% 55.8% 0.001
Mucoid P. aeruginosa 53.1% 42.0% 0.085
Burkholderia cepacia 5.2% 14.4% 0.016
Mucoid and nonmucoid P. aeruginosa 51.0% 21.85% <0.001
Spirometry Normal 27.3% 34.4% <0.001
Restrictive ventilatory disorder 18.2% 48.9%
Obstructive lung disorder 25.4% 14.5%
Mixed respiratory disorder 29.1% 2.3%
CFTR mutation F508del homozygotes 18.75% 26.5% <0.001
F508del heterozygotes 62.5% 22.7%
G542X 4.17% 6.45%
N1303K 2.08% 1.1%
G551D 1.04% –
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Table 1 Comparison of data (demographic, clinical, and laboratory markers) of patients with cystic fibrosis from a
Brazilian referral center during the decades of 1990 to 2000 and 2000 to 2010 (Continued)
R553X 0.52% 0.3%
W1282X 0.52% –
Shwachman-Kulczycki
score
Excellent or good 57.8% 36.2% 0.005
Mild 26.5% 36.2%
Moderate or severe 15.7% 27.6%
Deaths 18 31 1
Fecal balance 67.9% 80.0% 0.031
DI – period from 1990 to 2000; DII – period from 2000 to 2010; SpO2 – transcutaneous hemoglobin saturation by oxygen; p – p-value. Statistical analysis was performed
by the χ2 test. Statistically significant values are indicated by bold font. *Patients with two identified CFTR mutations.
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ated with variations in CF diagnosis and treatment [22].
Digestive disease, PI, and fecal balance
An important finding is that the digestive symptoms ex-
hibited the same frequency between the two decades.
Digestive symptoms are often the first clinical marker of
classic CF and are reported in 95% of patients withTable 2 Presence of digestive symptoms, comorbidities, and
fibrosis in a Brazilian referral center during the decades of 19
Decade Onset of digestive symptoms
Presence Absence T
1990–2000 62 (59.6%) 42 (40.4%)
2000–2010 151 (83.4%) 30 (16.6%)
Decade Meconium ileus
Presence Absence
1990–2000 6 (5.8%) 98 (94.2%)
2000–2010 27 (14.9%)
Decade Diabetes mellitus
Presence Absence
1990–2000 5 (4.8%) 99 (95.2%)
2000–2010 33 (18.2%) 148 (81.8%)
Decade Fecal fat balance
Presence Absence
1990–2000 71 (68.3%) 33 (31.7%)
2000–2010 145 (80.1%) 36 (24.2%)
Decade Weight percentile
P < 10 P≥ 10
1990–2000 73 (70.2%) 31 (29.8%)
2000–2010 35 (35.9%) 63 (64.1%)
Decade Height percentile
P < 10 P≥ 10
1990–2000 59 (56.7%) 45 (43.3%)
2000–2010 40 (40.9%) 58 (59.1%)
P – percentile; p – p-value; OR – odds ratio; CI – confidence interval. Statistical anal
by bold font.classic CF. Because no change in prevalence was ob-
served, this marker continues to be a target for first-line
treatment of patients with CF. After initial treatment,
the severity of symptoms and progression of lung disease
decrease.
The specific digestive symptoms associated with the
severity of CF are PI, DM, and MI. Among these digest-
ive symptoms, the principal marker of CF is PI. Apercentiles for weight and height in patients with cystic
90 to 2000 and 2000 to 2010
p-value OR 95% CI
otal
104 <0.001 0.295 0.17–0.51
181 1 –
p OR 95%CI
Total
104 0.021 0.35 0.11–0.91
181 1 –
p OR 95%CI
Total
104 0.001 0.228 0.07–0.61
181 1 –
p OR 95%CI
Total
104 0.031 0.534 (0.31–0.93)
181 1 –
p OR 95%CI
Total
104 <0.001 4.206 2.34–7.67
98 1 –
p OR 95%CI
Total
104 0.025 1.895 1.08–3.34
98 1 –
ysis was performed by the χ2 test. Statistically significant values are indicated
Table 3 Presence of bacteria in sputum samples of patients with cystic fibrosis in a Brazilian referral center during the
decades of 1990 to 2000 and 2000 to 2010
Decade Pseudomonas aeruginosa* p-value OR 95% CI
Presence Absence Total
1990–2000 79 (76.0%) 25 (24.0%) 104 0.001 2.495 1.42–4.48
2000–2010 101 (55.8%) 80 (44.2%) 181 1 –
Decade Burkholderia cepacia p-value OR 95%CI
Presence Absence Total
1990–2000 5 (4.8%) 99 (95.2%) 104 0.016 0.302 0.09–0.84
2000–2010 26 (14.4%) 155 (85.6%) 181 1 –
Decade Mucoid and nonmucoid P. aeruginosa# p-value OR 95%CI
Presence Absence Total
1990–2000 53 (51.0%) 51 (49.0%) 104 <0.001 3.645 2.11–6.38
2000–2010 40 (22.1%) 141 (77.9%) 181 1 –
OR – odds ratio; CI – confidence interval. Statistical analysis was performed by the χ2 test. Statistically significant values are indicated by bold font. *Analysis considering
the presence of nonmucoid P. aeruginosa isolated in culture. #Analysis considering the simultaneous presence of mucoid and nonmucoid P. aeruginosa.
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this study. PI is principally associated with severe CFTR
mutations and, secondarily, with modifier genes [23]. PI
screening was performed by fecal fat and/or fecal elas-
tase testing. Because no change in the diligence of PI
screening occurred in our center during the two de-
cades, we believe that the decreased frequency of PI with
time can be explained by the inclusion of patients with
mild CF.
Diagnosis and nutrition status
Patients with CF have better clinical outcomes when diag-
nosed earlier [24]. This fact was highlighted in the
comparison of DI and DII; both earlier diagnosis and
improved clinical outcomes were noted in DII. In
Brazil, the creation of the Brazilian Cystic Fibrosis
Study Group and the establishment of referral centers
have favored wider dissemination of CF screening guide-
lines. These facts contributed to the shorter diagnosis time
in DII. We found that in patients with severe CR, the diag-
nosis time did not differ between DI and DII. For patients
with less severe CF, however, the diagnosis time was
shorter in DII than in DI (this was only seen as a differ-
ence between the mean diagnosis times, not the median).
Early diagnosis and IRT screening are associated with
each other in patients with CF [25]. In the two decades
of the present study, however, IRT screening was not
used in our center. IRT screening was implemented in
our state at the end of the second decade (2010) and in
the entire country in 2014. Thus, we hope that in the
next decade, patients with CF will receive a diagnosis in
the first few months of life and that the clinical features
of CF will continue to improve with earlier intervention.
Patients with CF who maintain normal growth in the
first 2 years of diagnosis show better lung function, lesscoughing, and better chest radiographs at 6 years of age.
The benefits of IRT screening for pulmonary status at
6 years of age depend on the initial nutritional status
and are strongly associated with the need for compre-
hensive and consistent treatment implemented immedi-
ately after diagnosis [26,27]. In the present study, earlier
diagnosis in DII seemed to influence the nutritional sta-
tus. There were fewer patients with CF below the 10th
percentile for weight and height.
Comorbidities: DM and MI
The prevalence of DM was 4.8% in DI and 18.5% in DII.
This comorbidity is related to increased patient age, the
arising of modifier genes [28] secondary to the inflamma-
tory process, and consecutive destruction of the exocrine
pancreas [29]. The severity of CF was greater in female
than in male patients, especially during adolescence [30].
Patients with concurrent CF and DM have severe pulmon-
ary disease with a higher prevalence of pathogens in the
sputum, malnutrition, an increased incidence of liver dis-
ease, and increased mortality rates [30]. The recent in-
crease in life expectancy for patients with CF has caused
an increase in the prevalence of DM, and the mortality
rates for these patients remain high [31].
The prevalence of MI was lower in DI than in DII; the
prevalence in each decade was close to that cited in the
literature (14% and 11%, respectively) [32]. This probably
occurred because in DI, patients with concurrent CF
and MI died in the first year of life, before the diagnosis
of CF was confirmed [13,33].
Spirometry and lung disease
One of the most important markers of CF severity is the
decline in spirometry values throughout life, as more
than 90% of patients with CF die of lung disease. This
Table 4 Spirometry, Shwachman-Kulczycki scores, and prevalence of F508del mutation in patients with cystic fibrosis in a Brazilian referral center during the
decades of 1990 to 2000 and 2000 to 2010
Decade Spirometry Total
ORD OR (95% CI) MRD OR (95% CI) RVD OR (95% CI) Normal OR (95% CI)
1990–2000 14 (25.0%) 2.058 (0.87–4.79) 16 (29.8%) 17.58 (4.70–98.97) 10 (18.3%) 0.231 (0.10–0.51) 15 (26.9%) 0.719 (0.33–1.50) 55
2000–2010 19 (14.2%) 1 3 (2.2%) 1 66 (49.3%) 1 46 (34.3%) 1 134
Decade Clinical score Total
Moderate/Severe OR (95% CI) Mild OR (95% CI) Excellent/Good OR (95% CI)
1990–2000 13 (15.4%) 0.491 (0.24–0.96) 22 (26.9%) 0.635 (0.34–1.18) 48 (57.7%) 2.403 (1.40–4.16) 83
2000–2010 44 (27.5%) 1 58 (36.3%) 1 58 (36.3%) 1 160
Decade F508del mutation genotype Total
Homozygotes OR (95% CI) Heterozygotes OR (95% CI) Without F508del OR (95% CI)
1990–2000 19 (20.2%) 0.647 (0.34–1.21) 59 (61.5%) 5.445 (3.09–9.74) 18 (18.3%) 0.235 (0.13–0.42) 96
2000–2010 50 (27.6%) 1 41 (22.7%) 1 90 (49.7%) 1 181
OR – odds ratio; CI – confidence interval; ORD – obstructive respiratory disorder; MRD – mixed respiratory disorder; RVD – restrictive ventilatory disorder. Statistical analysis was performed by the χ2 test. Statistically
significant values are indicated by bold text.
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Table 5 Analysis of age of patients with cystic fibrosis in
a Brazilian referral center during the decades of 1990 to
2000 and 2000 to 2010
Age
groups
Decades p-value OR (95% CI)
1990–2000 2000–2010
Newborn 0 (0.0%) 0 (0.0%) <0.001 -
Infant 6 (7.0%) 6 (3.4%) 2.131 (0.63–7.19)
Preschool 25 (29.1%) 24 (13.6%) 2.602 (1.38–4.94)
Academic 18 (20.9%) 52 (29.4%) 0.636 (0.35–1.17)
Adolescent 27 (31.4%) 40 (22.6%) 1.567 (0.88–2.79)
Adult 10 (11.6%) 55 (31.0%) 0.293 (0.13–0.60)
OR – odds ratio; CI – confidence interval. Statistical analysis was performed by
the χ2 test. Statistically significant values are indicated by bold text.
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CFTR mutation, age at diagnosis, presence of PI, envir-
onmental pollution, nutritional status, adherence to
treatment, comorbidities (DM, depression, osteopenia,
and chronic infection), and sex. Airway changes caused
by CF first affect the small airways, followed by the lar-
ger airways and finally the pulmonary parenchyma. The
instruments used to measure pulmonary function have
different sensitivities and specificities. However, spirom-
etry is widely used to document longitudinal changes
because it is both inexpensive and noninvasive. A reduc-
tion in the incidence of obstructive lung disease and an
increase in the incidence of restrictive disorders was ob-
served as time progressed from DI to DII. CF is primar-
ily an obstructive lung disease, as observed in DI [34],
while restrictive disorders were more prevalent in DII.
Patients with class I, II, and III CFTR mutations have a
worse prognosis; however, with aggressive treatment
they can experience prolonged survival despite lower
lung function. No difference was observed in the SpO2
in this study.
Sweat chloride concentration
Measurement of the sweat chloride concentration by the
Gibson and Cooke method [35] is the gold standard for a
diagnosis of CF. Values of >60 mEq/L are indicative of
CF. In DI, 10.6%, 28.8%, and 60.6% of patients had a
sweat chloride concentration of 40 to 60, 60 to 100,
and >100 mEq/L, respectively. In DII, all patients with CF
had sweat chloride concentrations of >60 mEq/L. Patients
with sweat chloride concentrations of <60 mEq/L in DI
had other diagnostic criteria for CF such as respiratory
and digestive symptoms compatible with CF, colonization
by P. aeruginosa, and, principally, F508del mutation.
A difficult clinical problem is the assessment of indi-
viduals with signs and symptoms of CF but borderline
sweat chloride concentrations. The diagnosis of CF can
be clarified by evaporimetry, electrophysiology of epithe-
lial tissues (measurement of the nasal potential differenceand evaluation of the digestive epithelium using rectal bi-
opsy or an Ussing chamber), and CFTR mutation screen-
ing in patients with signs and symptoms of CF, but with
normal sweat test results [36-38].
Microorganisms
In patients with CF, morbidity and mortality are associ-
ated with chronic bronchial infection by various patho-
gens [36]. Recent evidence suggests that the presence of
such microorganisms along with opportunistic patho-
gens can affect the infection course and outcome [39].
No changes in the microbiologic profile of airway secre-
tions in patients with nonmucoid and mucoid P. aerugi-
nosa infection were observed between DI and DII. The
main factors associated with chronic colonization or in-
fection of airways by these bacteria in patients with CF
are environmental contamination, rigorous treatment for
the first colonization, screening diligence, increasing age,
and genetic modulation [40,41]. There was a higher fre-
quency of B. cepacia isolation in sputum from the patients
in DII. This finding may suggest that the environmental
prophylaxis adopted in our center is not appropriate be-
cause it indicates cross-contamination among patients.
Additionally, this increase may be due to the use of better
screening tools in our diagnostic routine (specific poly-
merase chain reaction for B. cepacia). These facts may
also account for the increased frequency of Achromobac-
ter xylosoxidans isolation in DII. Thus, increasing patient
age and diligence for B. cepacia identification by specific
means must have been responsible for the higher rates of
colonization and infection in DII.
CFTR genotype
Currently, patients with CF can be divided into two
groups using IRT screening: those with classic CF with
class I, II, and III mutations who reach adulthood be-
cause they have received pediatric care, and those with
CF caused by class IV, V, and VI mutations whose symp-
toms began in adolescence or adulthood.
Physicians who care for adults must consider these
two groups of patients with CF because they have differ-
ent genotypes and phenotypes. Future studies should
assess and share the developments and clinical and la-
boratory characteristics of these groups as patients with
typical and atypical CF. It is expected that patients with
classic CF will develop impaired lung function in child-
hood and exhibit a serious decline in function until
adulthood, while the same does not happen for patients
with CF with mild mutations, in whom lung function
values may be normal or near normal and who exhibit
only a mild to moderate decline in function over their
lifetime.
The most frequent CFTR mutations in this Brazilian
population differed between the two decades studied. A
Figure 1 Clinical outcome variables the between two decades of data for patients with cystic fibrosis from a Brazilian referral center.
SpO2, − transcutaneous hemoglobin saturation by oxygen; SKS, − Shwachman-Kulczycki score; M and NM, − mucoid and nonmucoid.
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prevalence of the heterozygous forms of the F508del mu-
tation were observed in DII. Additionally, a higher num-
ber of compound heterozygotes, but without screening of
the second mutation, was observed in DII. The failure to
identify the second mutation in a large group of patients,
even when the diagnosis of CF was clinically establishedand confirmed by two chloride level readings of >60 mEq/
L, makes comparison between the two decades difficult.
Two aspects of diagnosis that should be emphasized
are the use of F508del screening as the first step in
CFTR mutation screening [42] and the need for greater
attention on patients with CF diagnosed in adulthood
[43] than in pediatric patients with CF [44].
A 
B 
Onset of cystic fibrosis symptoms 
Cystic fibrosis diagnosis age 
Figure 2 Distribution of patients with cystic fibrosis according to ages at onset of symptoms and diagnosis. A. Comparison of the
distribution of patients with cystic fibrosis according to age at onset of symptoms between decades I (n = 95) and II (n = 181). B. Comparison of
distribution of patients with cystic fibrosis according to age at diagnosis between decades I (n = 100) and II (n = 180).
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The SKS measures clinical severity with consideration of
physical activity, radiographic findings, nutritional status,
and physical examination findings [15]. This scoring sys-
tem was created for children, but continues to be applied
to patients with CF of all ages. Scores are undoubtedly
needed for both children and adults covering all SKS char-
acteristics. There were fewer excellent/good scores and
more moderate/severe scores in DII than in DI. Similar to
the results of the other analyses between these two de-
cades, this finding can be explained because we are lead-
ing with the same population with class I, II, and III
mutations whose symptoms appear early in childhood and
who exhibit worsening of clinical and laboratory outcomes
until the beginning of adulthood.CF outcome-related death
There were 18 and 31 deaths in DI and DII, respectively.
There was no statistically significant difference in the
number of deaths between the two decades. The increase
in the number of deaths from DI to DII was proportionalto the increase in the number of patients seen from DI
to DII.
Study overview
From DI to DII in our center, the management, interdis-
ciplinary team, and conditions for CF diagnosis did not
change significantly. The fewer bacterial infections and
better nutrition in DII than in DI indicate the evolution
and importance of early diagnosis and management of CF.
These advancements provide patients with more hope and
a higher quality of life. Although many differences be-
tween the two decades were related to the earlier diagno-
sis in DII, the changes in some variables reflect the
association between the severity of CF and the aging
process, such as the worsening SKS.
The implementation of IRT screening in our state was
confirmed at the end of DII. In the next decade, this will
likely prove to be an important milestone on par with the
discovery of the CFTR gene in the late 1980s. Many pro-
fessionals currently working with patients with CF in
Brazil are participating in the implementation of the na-
tional IRT screening program. There are great expectations
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the health of both pediatric and adult Brazilian patients.
With time, new questions will emerge in the treatment
and management of patients with this intriguing patho-
physiological condition [45].
Study limitations
The patients’ records provided limited information in
some cases. Complete CFTR screening was not performed
in all patients with CF enrolled in the study. In DI, it was
not possible to collect information about the medications
used. Only one CF referral center was included in the
data, and inclusion of other centers was not possible be-
cause of the lack of information and mixed population
from our state. Numerical data for spirometry, weight,
height, SpO2, and SKS were completely recovered only for
DII; thus, we were unable to perform statistical tests for
numerical variables. Only one clinical score was obtained
in DI.
Conclusion
The clinical outcomes of CF changed from DI to DII in
our referral center. Demographic, clinical, and laboratory
analyses of patients with CF are useful and should be en-
couraged in referral centers worldwide. This will provide
information on the clinical evolution of CF according
newly available diagnostic tools, treatments, and man-
agement protocols. Furthermore, new studies on the
complex features of CF will provide better knowledge of
the disease. The outcomes of early diagnosis and man-
agement should be evaluated to provide a better quality
of life and longer life expectancy until a personalized
drug therapy is available for all CFTR class mutations.
Each day we take steps toward better clinical outcomes
for patients with CF, a pediatric disease with high mor-
tality in some cases and an adult lung disease in other
cases with better outcomes when diagnosis is performed
early in life. We will continue our studies to achieve a
cure for CF.
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